No Data
No Data
No Data
Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening With Multiple Data Presentations at DDW 2024
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the company will present six abstracts on strategies a
BusinesswireMay 7 08:00 ET
LabCorp Partner Geneoscopy Wins FDA Approval of Colorectal Cancer Test ColoSense
Seeking AlphaMay 6 16:35 ET
Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report
Earnings reports and a dovish stance from the Federal Reserve lifted stocks last week. Major indices reacted positively, particularly to earnings from high-profile companies that hold significant weig
BenzingaMay 6 05:25 ET
Earnings Week Ahead: Disney, Palantir, Shopify, Uber, Plug Power and More
Seeking AlphaMay 5 08:00 ET
There's No Escaping Exact Sciences Corporation's (NASDAQ:EXAS) Muted Revenues
With a price-to-sales (or "P/S") ratio of 4.4x Exact Sciences Corporation (NASDAQ:EXAS) may be sending very bullish signals at the moment, given that almost half of all the Biotechs companies in the U
Simply Wall StMay 2 08:33 ET
Exact Sciences to Participate in May Investor Conference
Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate
BusinesswireMay 1 06:00 ET